Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Autor: Christian Pfister, Valentin Harter, Yves Allory, François Radvanyi, Stéphane Culine, G. Grawis, G. Pignot, A. Flechon, J.P. Fendler, C. Chevreau, M. Soulie, H. Mahammedi, L. Guy, B. Laguerre, G. Verhoest, A. Guillot, N. Mottet, F. Joly, A. Doerfler, S. Abadie-Lacourtoisie, A.R. Azzouzi, P. Mongiat, L. Geoffrois, P. Eschwege, F. Di Fiore, G. Roubaud, J.L. Hoepffner, P. Barthelemy, H. Lang, E. Voog, E. Mandron, J.M. Tourani, C. Serrrate, A. Colau, C. Saldana, A. de La Taille, T. Nguyen, F. Kleinclauss, Y. Loriot, J. Irani, J.C. Eymard, S. Larre, O. Huillard, M. Zerbib, F. Rolland, J. Rigaud, N. Houede, S. Droupy, G. Malouf, M. Roupret, M. El Demery, C. Legon, S. Vieillot, N. Letang, T. Lharidon, N. Gaschignard, W. Hilgers, J.L. Davin

Publikováno v: Contemporary Clinical Trials Communications, Vol 17, Iss , Pp - (2020)

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery.A total of

Externí odkaz: https://doaj.org/article/f43ed578297242ffbca2d23538b428ab

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Autor: P. Eschwege, G. Verhoest, T. Nguyen, M. El Demery, G. Grawis, T. Lharidon, J.P. Fendler, C. Serrrate, H. Mahammedi, F. Di Fiore, N. Gaschignard, M. Zerbib, S. Droupy, C. Legon, N. Houédé, F. Kleinclauss, S. Vieillot, A. Colau, M. Soulié, François Radvanyi, G. Pignot, N. Letang, P. Barthelemy, Stéphane Culine, L. Guy, G. Malouf, P. Mongiat, J. Irani, A. Flechon, M. Roupret, L. Geoffrois, J.C. Eymard, J.M. Tourani, Valentin Harter, N. Mottet, O. Huillard, Y. Loriot, A. Doerfler, J. Rigaud, H. Lang, F. Rolland, Yves Allory, W. Hilgers, E. Voog, C. Chevreau, E. Mandron, S. Abadie-Lacourtoisie, A.R. Azzouzi, G. Roubaud, C. Saldana, S. Larre, J.L. Hoepffner, B. Laguerre, A. de la Taille, J.L. Davin, F. Joly, Christian Pfister, A. Guillot

Publikováno v: Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications, 2020, 17, pp.100536. ⟨10.1016/j.conctc.2020.100536⟩
Contemporary Clinical Trials Communications, Elsevier, 2020, 17, pp.100536. ⟨10.1016/j.conctc.2020.100536⟩
Contemporary Clinical Trials Communications, Vol 17, Iss, Pp-(2020)

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery.A total of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a83742ec45b00b0f6267e9cfb813078a
https://pubmed.ncbi.nlm.nih.gov/32083220